Neurocrine Biosciences names Eiry W. Roberts as Chief Medical Officer, replacing Sanjay Keswani.

Neurocrine Biosciences announced that Eiry W. Roberts, M.D., has rejoined as Chief Medical Officer, replacing Sanjay Keswani by mutual agreement. Dr. Roberts previously served as CMO from 2018 to 2025 and has been a Strategic Advisor since. Her return provides continuity as the company advances multiple late-stage clinical programs and prepares for key milestones. The company highlighted her experience leading successful drug development efforts, including FDA approvals for CRENESSITY and INGREZZA.

Neurocrine Biosciences (NBIX) shares are trading at USD 140.25 on Pluang as of Sep 29, 2026 03:12 WIB, which is closer to its 52-week low of USD 123.10 than its high of USD 185.50. The stock has gained 1.54% in the last day, reflecting moderate positive momentum. Investor activity on Pluang is evenly split between buying and selling, with a typical hold time of 21 days, indicating balanced sentiment around the company during this leadership transition.